Claims:

1. A crystalline compound of Formula (I):



(I)

that produces a powder X-ray diffraction spectrum comprising peaks at diffraction angles (2Θ±0.2º) of 18.5 and 19.3.

2. The crystalline compound of claim 1, further comprising peaks at diffraction angles (2Θ±0.2º) of 21.1 and 22.2.

3. The crystalline compound of claim 1 or 2, further comprising peaks at diffraction angles (2Θ±0.2º) of 7.4, 9.6, 14.7, and 16.7.

4. A crystalline compound of Formula (I):



(I)

wherein at least about 90% by wt. of the total amount of the crystalline compound of Formula (I) is crystalline Form A, which produces a powder X-ray diffraction spectrum comprising at least three peaks at diffraction angles (2Θ±0.2º) selected from 7.4, 9.6, 14.7, 16.7, 17.1, 18.5, 19.3, 21.1, and 22.2.

5. The crystalline compound of any one of claims 1 to 4, wherein the crystalline compound has a particle size D_{90} of 15 µm.

6. The crystalline compound of any one of claims 1 to 4, wherein the crystalline compound has a particle size D_{90} of 8 µm.

7. A crystalline compound of Formula (I):



(I)

that produces a powder X-ray diffraction spectrum as shown in FIG. 3A.

8. A crystalline compound of Formula (I):



(I)

that has a differential scanning calorimetry (DSC) thermogram with an endothermic event having a peak temperature at about 241°C.

9. A pharmaceutical composition comprising a crystalline compound according to any one of claims 1 to 8, and at least one pharmaceutically acceptable excipient.

10. A dosage unit comprising from about 0.16 mg to about 8.0 mg of a crystalline compound according to any one of claims 1 to 8.

11. The dosage unit of claim 10, wherein the dosage unit is a solid oral dosage form.

12. The dosage unit of claim 11, wherein the solid oral dosage for is a tablet or capsule.

13. The dosage unit of any one of claims 10 to 12, wherein the dosage unit comprises from about 0.5 mg to about 6.0 mg of the crystalline compound of Formula (I).

14. The dosage unit of any one of claim 10 to 12, wherein the dosage unit comprises from about 0.5 mg to about 3.0 mg of the crystalline compound of Formula (I).

15. A process for producing a crystalline compound of Formula (I):



(I)

in crystalline Form A comprising the steps:

dissolving a compound of Formula (I) in formic acid to form a solution;

diluting the solution with ethyl acetate solvent to form a diluted solution;

forming a slurry in the diluted solution; and

filtering the slurry to isolate the crystalline Form A of Formula (I) form, which produces a powder X-ray diffraction spectrum comprising at least three peaks at

diffraction angles (degrees 2Θ±0.2º) selected from 7.4, 9.6, 14.7, 16.7, 17.1, 18.5, 19.3, 21.1, and 22.2.

16. The process of claim 15, further comprising the step of adding *p*-toluenesulfonic acid to the solution.

17. Use of the crystalline compound according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment, prevention or management of a sleep disorder.

18. The use according to claim 17, wherein the sleep disorder is selected from the group consisting of insomnia; an alcohol-induced sleep disorder; insomnia in alcohol use disorder; a sleep disturbance associated with alcohol cessation; hypersomnia; circadian rhythm sleep-wake disorder; or any combination thereof.

19. The crystalline compound according to any one of claims 1 to 8 for use in the treatment, prevention or management of a sleep disorder.

20. The crystalline compound for use according to claim 19, wherein the sleep disorder is selected from the group consisting of insomnia; an alcohol-induced sleep disorder; insomnia in alcohol use disorder; a sleep disturbance associated with alcohol cessation; hypersomnia; circadian rhythm sleep-wake disorder; or any combination thereof.